10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

In a report released today, Luke Sergott from Barclays maintained a Buy rating on 10x Genomics (TXG – Research Report), with a price target of $12.00. The company’s shares closed yesterday at $8.67.

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & services industry, including 10x Genomics (NASDAQ:TXG) and its peers.

EDT Cathie Wood’s ARK Investment buys 191.5K shares of 10x Genomics (TXG) todayStay Ahead of the Market: Discover outperforming stocks ...

DUBLIN and SAN DIEGO, March 27, 2025 /PRNewswire/ -- ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Jumpcode Genomics ('Jumpcode'), a life science tools company improving and ...